<DOC>
	<DOCNO>NCT00758030</DOCNO>
	<brief_summary>The purpose study evaluate compare pharmacokinetics ER OROS paliperidone healthy Japanese Caucasian patient .</brief_summary>
	<brief_title>Study Evaluating Comparing Single Dose Multiple Dose Pharmacokinetics ER OROS Paliperidone Healthy Japanese Caucasian Adults .</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double blind ( neither physician patient know name study medication/placebo assign ) study compare single ( SD ) multiple dose ( MD ) pharmacokinetics ER OROS paliperidone 30 healthy Japanese 30 healthy Caucasian adults.. The primary objective study 1 ) evaluate safety tolerability extended-release ( ER ) OROS paliperidone healthy Japanese adult , 2 ) evaluate single dose ( SD ) multiple dose ( MD ) pharmacokinetics ER OROS paliperidone healthy Japanese adult , 3 ) compare SD MD pharmacokinetics ER OROS paliperidone healthy Japanese Caucasian adult . Of 30 Japanese patient enrol , least 10 men 10 woman . An equal number Caucasian patient , match closely possible Japanese subject sex , age , weight , enrol . Patients randomly assign receive either ER OROS paliperidone placebo ( 4:1 ratio ) . Blood sample determination paliperidone enantiomer plasma concentration collect immediately prior dose Days 1 , 9 , 10 , 11 , 19 , 2 , 4 , 6 , 9 , 12 , 16 , 18 , 20 , 22 , 24 , 27 , 33 , 36 , 48 , 58 , 72 , 96 hour dose Days 1 , 11 , 19 . Urine sample collect predose 0-12 , 12-24 , 24-36 , 36-48 hour interval dose Days 1 19 0-12 12-24 hour interval dose Day 11 ; separate aliquot take pool 0-24 hour urine urine creatinine concentration Days 1 , 11 , 19 . Plasma urine sample analyze use validated LC-MS/MS method limit quantification 0.200 ng/mL 1 ng/mL , respectively . The concentration paliperidone plasma urine calculate sum separate enantiomer . Based actual sampling time , plasma pharmacokinetic parameter determine paliperidone enantiomers.Safety evaluation base report adverse event , extrapyramidal symptom ( reported adverse event Abnormal Involuntary Movement Scale [ AIMS ] , Simpson Angus Scale [ SAS ] , Barnes Akathisia Rating Scale [ BARS ] ) , sedation ( base Sedation Visual Analog Scale [ VAS ] Sedation Questionnaire ) , change baseline clinical laboratory analyte value , vital sign measurement , orthostatic hypotension ( base Orthostatic Hypotension Questionnaire ) , postural change blood pressure heart rate , electrocardiogram , physical examination finding . Paliperidone ER OROS tablet formulation ( 3 6 mg/day ) take orally . Patients randomly assign receive either ER OROS paliperidone placebo ( 4:1 ratio ) . All patient receive single dose 3 mg ER OROS paliperidone ( placebo ) Day 1 , daily regimen 3 mg ER OROS paliperidone ( placebo ) Days 5 11 , single dose 6 mg ER OROS paliperidone ( placebo ) Day 19 . All dos administer fasted state .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Healthy Japanese Caucasian patient . Japanese patient bear Japan Japanese parent live outside Japan 5 year Normotensive ( 5 minute lie systolic blood pressure 100139 mmHg diastolic blood pressure 6089 mmHg ) Body Mass Index 18 25 kg/m2 Considered healthy base medical history , prestudy physical examination finding , electrocardiogram , clinical laboratory evaluation chemistry , hematology , urinalysis value . History significant cardiovascular , respiratory , neurologic , renal , hepatic , endocrine , psychiatric , immunologic disorder Use concomitant medication , except paracetamol hormonal contraceptive Has receive experimental drug and/or use experimental medical device 60 day first dose .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
</DOC>